Recognify Life Sciences

Executive Summary

Recognify Life Sciences, a subsidiary of atai Life Sciences, is a clinical-stage biotechnology company developing RL-007, a novel treatment for Cognitive Impairment Associated with Schizophrenia (CIAS). CIAS affects a majority of schizophrenia patients and represents a significant unmet medical need with no approved therapies. RL-007 is a Phase 2-ready compound with a differentiated mechanism targeting nicotinic acetylcholine receptors, aimed at improving cognitive function. The company is positioned to address a large market opportunity, leveraging atai's infrastructure and expertise in mental health therapeutics. As a private entity, Recognify benefits from atai's financial and strategic support, reducing near-term funding risk. The upcoming initiation of Phase 2 trials will be a critical value inflection point, with potential for positive data to de-risk the program and attract partnership interest. However, the early-stage nature and competitive landscape in cognitive disorders warrant cautious optimism. Successful execution of clinical development could position RL-007 as a first-in-class therapy for CIAS, offering significant upside.

Upcoming Catalysts (preview)

• Q3 2026Initiation of Phase 2 trial for RL-007 in CIAS80% success
• H2 2026Presentation of preclinical or mechanism of action data at a medical conference70% success
• Q4 2026Potential strategic partnership or licensing deal for RL-007 outside of atai40% success